The Mir155 reporter assay in Th17 cells was used to screen FDA approved drugs with the intent to use these pre-existing drugs to treat autoimmunity as CD4+ Th17 cells express relatively high amounts of miR-155 relative to other CD4+ T cell subsets. This evidence concerns the gene CD4 and Autoimmunity.